Follow CGSP on Social Media

Listen to the CGSP Podcast

China’s Vaccine Push in Developing Countries Suffers Setback After Brazillian Tests Reveal Sinovac’s Shot Only 50% Effective

A package of the experimental vaccine test for the COVID-19 coronavirus is pictured at the Quality Control Laboratory at the Sinovac Biotech facilities in Beijing. NICOLAS ASFOURI / AFP

China’s ambitious global drive to provide developing countries with affordable COVID-19 vaccines suffered a major setback on Tuesday following new test results from Brazil that revealed Sinovac’s CoronaVac vaccine to be only 50% effective.

The findings from the Butantan Institute, a São Paulo-based public institute that is the first to complete late-stage trials of the CoronaVac vaccine, came as a big surprise because just last week the institute said Sinovac’s shot was 78% effective and offered total protection against severe cases of the disease.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Full access to the News Feed that provides daily updates on Chinese engagement in Africa and throughout the Global South.

China, Africa and the Global South... find out what’s happening.

Subscribe today for unlimited access.

What is The China-Global South Project?


The China-Global South Project is passionately independent, non-partisan and does not advocate for any country, company or culture.


A carefully curated selection of the day’s most important China-Global South stories. Updated 24 hours a day by human editors. No bots, no algorithms.


Diverse, often unconventional insights from scholars, analysts, journalists and a variety of stakeholders in the China-Global South discourse.


A unique professional network of China-Africa scholars, analysts, journalists and other practioners from around the world.